1. Home
  2. FISV vs BIIB Comparison

FISV vs BIIB Comparison

Compare FISV & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fiserv Inc.

FISV

Fiserv Inc.

N/A

Current Price

$49.17

Market Cap

28.7B

Sector

Real Estate

ML Signal

N/A

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$197.65

Market Cap

27.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FISV
BIIB
Founded
1984
1978
Country
United States
United States
Employees
38000
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.7B
27.3B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
FISV
BIIB
Price
$49.17
$197.65
Analyst Decision
Buy
Buy
Analyst Count
28
25
Target Price
$146.17
$206.83
AVG Volume (30 Days)
7.2M
846.3K
Earning Date
05-05-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.15
Revenue
N/A
$9,890,600,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.94
N/A
P/E Ratio
$9.94
$90.98
Revenue Growth
N/A
2.22
52 Week Low
$47.37
$121.06
52 Week High
$70.41
$205.97

Technical Indicators

Market Signals
Indicator
FISV
BIIB
Relative Strength Index (RSI) 35.62 55.26
Support Level N/A $184.00
Resistance Level $64.56 $202.73
Average True Range (ATR) 2.19 5.72
MACD -0.60 0.04
Stochastic Oscillator 12.30 74.18

Price Performance

Historical Comparison
FISV
BIIB

About FISV Fiserv Inc.

Fiserv is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Following its 2019 merger with First Data, Fiserv also provides payment processing services to merchants. About 10% of the company's revenue is generated internationally.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: